Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Teknova makes the liquid ingredients and chemical building blocks that biotech companies need to grow cells and run lab tests.
Teknova is a supplier to the life sciences industry — the company sells the liquids, powders, and chemical ingredients that biotech and diagnostic companies need to grow cells, run experiments, and manufacture drugs. Its main products are cell culture media (the nutrient broth that keeps living cells alive outside the body), molecular biology reagents, and custom chemical formulations. Customers include drug developers, diagnostic labs, and research institutions, and Teknova's pitch is speed and customization: it can mix up a specific recipe to a customer's exact specifications and ship it fast, rather than forcing them to buy a one-size-fits-all catalog product.

The business sits at the very beginning of the drug-making chain, which is both its strength and its weakness. On one hand, once a customer validates a reagent in their process — especially in a regulated drug manufacturing workflow — switching suppliers means redoing expensive testing, so they tend to stick around. On the other hand, Teknova is tiny compared to the giants it competes with, like Thermo Fisher Scientific and Merck KGaA (the German Merck, not the US one), and its customers are biotech companies whose spending rises and falls with the funding cycle. When biotech venture money dries up, small drug developers cut back on lab supplies, and Teknova feels it quickly. That vulnerability showed up painfully after the pandemic. Teknova went public on Nasdaq in 2021 during the boom in biotech research spending, but as funding cooled, its revenue slumped and the company has been working to steady itself — cutting costs, sharpening its focus on higher-value custom work, and trying to grow its way back. The company is headquartered in Hollister, California, a small agricultural town south of Silicon Valley, where it runs its manufacturing.
The deeper bet here is on the long-term growth of biological medicine: as more drugs are made from living cells rather than chemistry, demand for the specialized nutrients and reagents that keep those cells happy should grow. Teknova is a small, specialized supplier trying to ride that wave without the balance sheet of its much larger rivals. It's a real business with sticky customer relationships, but it's also a cyclical, subscale player in a market dominated by giants — a company whose fortunes hinge on whether biotech research budgets are open or closed.
Saved answer · last researched 16 Nov 2026